Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
GNW Transcript
Genworth Financial, Inc. (GNW) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call presented a mixed picture: strong share repurchase activity and solid Enact performance are positives, but future premium approvals and Closed Block losses present risks. The Q&A highlighted management's confidence in RBC ratio management and strategic plans to counteract pressures. However, the lack of explicit reasons for financial changes and the uncertainty around future premium approvals and Closed Block sustainability temper overall sentiment. Given the company's market cap and mixed signals, a neutral stock price movement is expected.
Genworth Financial, Inc. (GNW) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reveals strong financial performance from Enact, a significant share repurchase program, and optimistic guidance for CareScout's expansion. Despite some risks, such as scaling challenges and regulatory hurdles, the company's strategic investments and capital returns are well-received. The Q&A section highlights management's confidence in CareScout's dual approach, further boosting sentiment. Given the company's market cap, these positive aspects are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Genworth Financial, Inc. (GNW) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals mixed signals. Financial performance shows strong net income and liquidity, but losses in the LTC segment and unclear long-term strategies raise concerns. The Q&A highlights management's vague responses, especially on statutory income and LTC resolution, which may worry investors. The share repurchase plan and potential AXA litigation proceeds are positives, but the lack of clear guidance tempers optimism. Given the market cap, the stock is likely to remain stable, resulting in a neutral sentiment.
Genworth Financial, Inc. (GNW) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call summary presents a mixed picture: strong shareholder returns and a promising new product development, but also significant losses in LTC and corporate sectors. The Q&A section reveals management's confidence but also highlights uncertainties, particularly around legal proceedings and the appeal process. The company's strategic focus on share buybacks is positive, but the absence of dividends and unclear management responses to some questions add to the uncertainty. Considering the market cap, the overall sentiment is neutral, with no major catalysts to drive significant stock price movement.
GNW Slides
GNW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
